HBL
MCID: HPT022
MIFTS: 56

Hepatoblastoma (HBL)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hepatoblastoma

MalaCards integrated aliases for Hepatoblastoma:

Name: Hepatoblastoma 12 76 53 29 55 6 44 15 73
Hbl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:687
ICD10 33 C22.2
MeSH 44 D018197
NCIt 50 C3728
SNOMED-CT 68 45024009
UMLS 73 C0206624

Summaries for Hepatoblastoma

NIH Rare Diseases : 53 Hepatoblastoma is a rare malignant (cancerous) tumor of the liver that usually occurs in the first 3 years of life. In early stages of the condition, there may be no concerning signs or symptoms. As the tumor gets larger, affected children may experience a painful, abdominal lump; swelling of the abdomen; unexplained weight loss; loss of appetite; and/or nausea and vomiting. The exact underlying cause of hepatoblastoma is poorly understood. Risk factors for the tumor include prematurity with a very low birth weight, early exposure to hepatitis B infection, biliary atresia, and several different genetic conditions (i.e. Beckwith-Wiedemann syndrome, familial adenomatous polyposis, Aicardi syndrome, Glycogen storage disease, and Simpson-Golabi-Behmel syndrome). Treatment varies based on the severity of the condition but may include a combination of surgery, watchful waiting, chemotherapy, and/or radiation therapy.

MalaCards based summary : Hepatoblastoma, also known as hbl, is related to beckwith-wiedemann syndrome and hepatocellular carcinoma, and has symptoms including icterus An important gene associated with Hepatoblastoma is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Lenograstim and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include liver, fetal liver and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Hepatoblastoma is an uncommon malignant liver cancer occurring in infants and children and composed of... more...

Related Diseases for Hepatoblastoma

Diseases related to Hepatoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
# Related Disease Score Top Affiliating Genes
1 beckwith-wiedemann syndrome 32.1 AFP CDKN1C GPC3 H19 IGF2 TP53
2 hepatocellular carcinoma 31.8 ABCB1 AFP APC BIRC5 CASP3 CRNDE
3 familial adenomatous polyposis 30.7 APC CTNNB1 TP53
4 teratoma 30.2 AFP KRT7 TP53
5 embryonal sarcoma 30.2 CTNNB1 GPC3 TP53
6 adenocarcinoma 30.0 APC BIRC5 CTNNB1 H19 TP53
7 familial adenomatous polyposis 1 30.0 APC CTNNB1
8 adenoma 29.9 APC CTNNB1 PLAG1 TP53
9 hemihyperplasia, isolated 29.6 CDKN1C H19 IGF2
10 cholangiocarcinoma 29.0 AFP APC CTNNB1 GPC3 H19 HGF
11 lung cancer susceptibility 3 28.7 APC BIRC5 CASP3 CTNNB1 H19 HGF
12 mixed hepatoblastoma 12.3
13 macrotrabecular hepatoblastoma 12.1
14 hypobetalipoproteinemia, familial, 2 11.3
15 chylomicron retention disease 11.1
16 hepatitis 10.3
17 desmoid disease, hereditary 10.3 APC CTNNB1
18 silver-russell syndrome due to an imprinting defect of 11p15 10.3 H19 IGF2
19 silver-russell syndrome due to 11p15 microduplication 10.3 H19 IGF2
20 adult hepatocellular carcinoma 10.3 CTNNB1 TP53
21 beckwith-wiedemann syndrome due to imprinting defect of 11p15 10.3 H19 IGF2
22 hepatitis b 10.3
23 intestinal benign neoplasm 10.3 APC CTNNB1 TP53
24 short-rib thoracic dysplasia 4 with or without polydactyly 10.3 CASP3 TP53
25 hyperplastic polyposis syndrome 10.2 APC TP53
26 peutz-jeghers syndrome 10.2 APC CTNNB1 TP53
27 colorectal adenoma 10.2 APC CTNNB1 TP53
28 atypical teratoid rhabdoid tumor 10.2 CTNNB1 IGF2 TP53
29 testicular malignant germ cell cancer 10.2 AFP GPC3
30 pharynx cancer 10.2 CASP3 CTNNB1 TP53
31 nasopharyngeal disease 10.2 CASP3 CTNNB1 TP53
32 embryoma 10.2 AFP GPC3 IGF2
33 cervix disease 10.2 CASP3 CTNNB1 TP53
34 anaplastic thyroid cancer 10.2 CASP3 CTNNB1 TP53
35 male reproductive organ cancer 10.2 CASP3 CTNNB1 TP53
36 meninges sarcoma 10.2 IGF2 TP53
37 colonic disease 10.2 CASP3 CTNNB1 TP53
38 tongue cancer 10.2 CASP3 CTNNB1 TP53
39 ovarian embryonal carcinoma 10.2 AFP GPC3
40 stomach disease 10.2 CASP3 CTNNB1 TP53
41 female reproductive system disease 10.2 CASP3 CTNNB1 TP53
42 reproductive system disease 10.2 CASP3 CTNNB1 TP53
43 marek disease 10.2 H19 TP53
44 respiratory system cancer 10.2 CASP3 CTNNB1 TP53
45 germ cell cancer 10.2 AFP H19 IGF2
46 testicular germ cell tumor 10.2 AFP GPC3 TP53
47 bladder transitional cell papilloma 10.2 BIRC5 TP53
48 intestinal disease 10.2 CASP3 CTNNB1 TP53
49 neuroblastoma 10.2
50 hepatic adenomas, familial 10.2 AFP APC CTNNB1 GPC3

Graphical network of the top 20 diseases related to Hepatoblastoma:



Diseases related to Hepatoblastoma

Symptoms & Phenotypes for Hepatoblastoma

UMLS symptoms related to Hepatoblastoma:


icterus

GenomeRNAi Phenotypes related to Hepatoblastoma according to GeneCards Suite gene sharing:

26 (show all 23)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.97 CTNNB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.97 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.97 AFP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.97 IGF2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.97 AFP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.97 IGF2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.97 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.97 KRT7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.97 IGF2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.97 IGF2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.97 APC CTNNB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.97 AFP APC KRT7
13 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.97 IGF2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.97 CTNNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.97 APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.97 AFP APC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.97 CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.97 APC CTNNB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.97 AFP IGF2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.97 CTNNB1 IGF2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.97 CTNNB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.97 APC KRT7 CTNNB1 IGF2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.97 CTNNB1 IGF2

MGI Mouse Phenotypes related to Hepatoblastoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 ABCB1 APC APOA1 CASP3 CDO1 CTNNB1
2 cellular MP:0005384 10.28 APC APOA1 BIRC5 CASP3 CTNNB1 GPC3
3 homeostasis/metabolism MP:0005376 10.25 ABCB1 AFP APC APOA1 BIRC5 CASP3
4 endocrine/exocrine gland MP:0005379 10.22 ABCB1 AFP APC APOA1 BIRC5 CASP3
5 embryo MP:0005380 10.1 APC BIRC5 CTNNB1 GPC3 HGF IGF2
6 mortality/aging MP:0010768 10.1 ABCB1 AFP APC BIRC5 CASP3 CDO1
7 craniofacial MP:0005382 10.07 APC CASP3 CDO1 CTNNB1 GPC3 IGF2
8 digestive/alimentary MP:0005381 10.05 ABCB1 APC CASP3 CTNNB1 GPC3 IGF2
9 liver/biliary system MP:0005370 10.02 ABCB1 AFP APC APOA1 CTNNB1 HGF
10 integument MP:0010771 10.01 APC APOA1 CASP3 CTNNB1 GPC3 IGF2
11 hearing/vestibular/ear MP:0005377 9.93 ABCB1 APC CASP3 CDO1 CTNNB1 TP53
12 no phenotypic analysis MP:0003012 9.8 ABCB1 APC CASP3 CTNNB1 HGF IGF2
13 pigmentation MP:0001186 9.55 APC CASP3 CTNNB1 GPC3 TP53
14 renal/urinary system MP:0005367 9.5 APC CASP3 CTNNB1 GPC3 IGF2 KRT7
15 reproductive system MP:0005389 9.32 ABCB1 AFP APC CASP3 CDO1 CTNNB1

Drugs & Therapeutics for Hepatoblastoma

Drugs for Hepatoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 1,Not Applicable 135968-09-1
2
Nicotine Approved Phase 4 54-11-5 942 89594
3 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Adjuvants, Immunologic Phase 4,Phase 1,Not Applicable
5
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
6
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
7
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
8
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
9
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
10
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
11
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
12
Amifostine Approved, Investigational Phase 3,Phase 1 20537-88-6 2141
13
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 3 61825-94-3 43805 6857599 5310940 9887054
14
Sorafenib Approved, Investigational Phase 2, Phase 3,Phase 3 284461-73-0 216239 406563
15
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1 95058-81-4 60750
16
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
17
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
18
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
20
Sevoflurane Approved, Vet_approved Phase 2, Phase 3 28523-86-6 5206
21
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
22
Rocuronium Approved Phase 2, Phase 3 119302-91-9, 143558-00-3 441290
23
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
24
Cyproheptadine Approved Phase 3 129-03-3 2913
25
Doxil Approved June 1999 Phase 3,Phase 2 31703
26
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
27 Liver Extracts Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
31 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
33 Etoposide phosphate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
34 topoisomerase I inhibitors Phase 2, Phase 3,Phase 3,Phase 1
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
36 Radiation-Protective Agents Phase 3,Phase 1
37 Antimetabolites Phase 3,Phase 2,Phase 1
38 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Protective Agents Phase 3,Phase 1,Not Applicable
40 sodium thiosulfate Phase 3
41 Anti-Infective Agents Phase 3,Phase 2,Phase 1
42 Antioxidants Phase 3
43 Antitubercular Agents Phase 3
44 Chelating Agents Phase 3
45 Antidotes Phase 3
46 Keratolytic Agents Phase 2, Phase 3
47 Antiviral Agents Phase 2, Phase 3,Phase 3,Phase 1
48 Podophyllotoxin Phase 2, Phase 3 518-28-5
49 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3
50 Dermatologic Agents Phase 2, Phase 3,Phase 3

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
2 Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer Completed NCT00003994 Phase 3 cisplatin;vincristine sulfate;fluorouracil;amifostine trihydrate;carboplatin
3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
4 Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer Completed NCT00652132 Phase 3 cisplatin;sodium thiosulfate
5 Chemotherapy in Treating Children With Liver Cancer Completed NCT00003912 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride
6 Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Recruiting NCT03533582 Phase 2, Phase 3 Carboplatin;Cisplatin;Doxorubicin;Etoposide;Fluorouracil;Gemcitabine;Irinotecan;Oxaliplatin;Sorafenib;Vincristine Sulfate
7 Paediatric Hepatic International Tumour Trial Recruiting NCT03017326 Phase 3 Cisplatin;Doxorubicin;Carboplatin;5Fluorouracil;Vincristine;Etoposide;Irinotecan;Gemcitabine;Oxaliplatin;Sorafenib
8 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Active, not recruiting NCT00980460 Phase 3 Cisplatin;Dexrazoxane;Doxorubicin Hydrochloride;Fluorouracil;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
9 the Efficacy and Safety of Sugammadex in Children 0-2 Years Old Not yet recruiting NCT03728543 Phase 2, Phase 3 Sugammadex
10 Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
11 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
12 Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma Unknown status NCT00287976 Phase 2 irinotecan hydrochloride
13 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Unknown status NCT00077389 Phase 2 carboplatin;cisplatin;doxorubicin hydrochloride
14 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
15 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed NCT01125800 Phase 1, Phase 2 LDE225
16 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
17 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
18 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
19 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
20 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Recruiting NCT01956669 Phase 2 Pazopanib GW786034
21 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
22 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03526250 Phase 2 Palbociclib
23 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03698994 Phase 2 Ulixertinib
24 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
25 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03220035 Phase 2 Vemurafenib
26 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03233204 Phase 2 Olaparib
27 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib
28 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
29 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib
30 Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Recruiting NCT01804634 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Sirolimus
31 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Suspended NCT03213665 Phase 2 Tazemetostat
32 Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Withdrawn NCT02011126 Phase 2 Imetelstat Sodium
33 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
34 EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT03618381 Phase 1
35 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1 Simvastatin;Cyclophosphamide;Topotecan;Myeloid growth factor
36 A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy Recruiting NCT02085148 Phase 1 Regorafenib (BAY73-4506);Vincristine (Cellcristin®);Irinotecan (Irinotecan Cell pharm®)
37 Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors Recruiting NCT03507491 Phase 1 Gemcitabine;Nab-paclitaxel
38 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting NCT01331135 Phase 1 sirolimus
39 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1 amifostine trihydrate;busulfan;filgrastim;melphalan;thiotepa
40 MT2004-30: Tomotherapy for Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
41 Cancer and Hearing Loss Related in Children Unknown status NCT02425397
42 Biomarkers in Tissue Samples From Young Patients With Liver Cancer Completed NCT01336881
43 Collecting and Storing Tissue From Young Patients With Cancer Completed NCT00898755
44 Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer Completed NCT01353300
45 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
46 Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience Recruiting NCT02557750
47 Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Recruiting NCT01505569 Not Applicable Ifosfamide;Etoposide;Mesna;Busulfan;Melphalan;Thiotepa;Carboplatin;Paclitaxel;Anti-seizure prophylaxis;Ursodiol
48 Diagnostic Accuracy of PIVKA-II Combining With Alpha-Fetoprotein in Hepatic Tumor Not yet recruiting NCT03645655
49 Hepatoblastoma Biology Study and Tissue Bank Withdrawn NCT00228683 Not Applicable
50 Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors Withdrawn NCT00624962 Not Applicable

Search NIH Clinical Center for Hepatoblastoma

Cochrane evidence based reviews: hepatoblastoma

Genetic Tests for Hepatoblastoma

Genetic tests related to Hepatoblastoma:

# Genetic test Affiliating Genes
1 Hepatoblastoma 29

Anatomical Context for Hepatoblastoma

MalaCards organs/tissues related to Hepatoblastoma:

41
Liver, Fetal Liver, Brain, Lung, Kidney, Bone, Myeloid

Publications for Hepatoblastoma

Articles related to Hepatoblastoma:

(show top 50) (show all 1136)
# Title Authors Year
1
Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome. ( 30270492 )
2019
2
Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma. ( 30160353 )
2019
3
Results of surgical resections with positive margins for children with hepatoblastoma: Case series from a single Asian center. ( 30255649 )
2019
4
Treatment outcome and pattern of failure in hepatoblastoma treated with a consensus protocol in Hong Kong. ( 30270490 )
2019
5
Targeting LRH‑1 in hepatoblastoma cell lines causes decreased proliferation. ( 30320362 )
2019
6
Reiterative Radiofrequency Ablation in the Management of Pediatric Patients with Hepatoblastoma Metastases to the Lung, Liver, or Bone. ( 30350173 )
2019
7
Microscopically positive resection margin after hepatoblastoma resection: what is the impact on prognosis? A Childhood Liver Tumours Strategy Group (SIOPEL) report. ( 30528797 )
2019
8
Prognostic and therapeutic factors influencing the clinical outcome of hepatoblastoma after liver transplantation: A single-institute experience. ( 29341393 )
2018
9
Two Cases of Hepatoblastoma in Young Adults. ( 29412770 )
2018
10
Long-term outcomes of liver transplantation for hepatoblastoma: A single-center 14-year experience. ( 29888545 )
2018
11
A novel tissue-based A9-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors. ( 29446530 )
2018
12
Pediatric hepatoblastoma and hepatocellular carcinoma: lessons learned in the last decade. ( 29383417 )
2018
13
Oridonin increases anticancer effects of lentinan in HepG2 human hepatoblastoma cells. ( 29434900 )
2018
14
Pediatric patient with end-stage kidney disease secondary to Eagle-Barrett syndrome and metastatic unresectable hepatoblastoma treated successfully with chemotherapy and liver-kidney transplant. ( 29356335 )
2018
15
20(S)-Protopanaxadiol induces apoptosis in human hepatoblastoma HepG2 cells by downregulating the protein kinase B signaling pathway. ( 29434714 )
2018
16
Hepatoblastoma in a child with dextrocardia and possible histopathological alteration reminiscent of hepatocellular carcinoma after neoadjuvant chemotherapy. ( 29881566 )
2018
17
Hepatoblastoma: current understanding, recent advances, and controversies. ( 29375822 )
2018
18
Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival. ( 29755772 )
2018
19
Comprehensive analysis and experimental verification of LINC01314 as a tumor suppressor in hepatoblastoma. ( 29571247 )
2018
20
Metastasectomy of Hepatoblastoma Utilizing a Novel Overlay Fluorescence Imaging System. ( 29906233 )
2018
21
Chrysotoxene induces apoptosis of human hepatoblastoma HepG2 cells <i>in vitro</i> and <i>in vivo</i> via activation of the mitochondria-mediated apoptotic signaling pathway. ( 29541233 )
2018
22
Single-walled carbon nanohorn aggregates promotes mitochondrial dysfunction-induced apoptosis in hepatoblastoma cells by targeting SIRT3. ( 29956732 )
2018
23
Expression Profiling Identifies Circular RNA Signature in Hepatoblastoma. ( 29414822 )
2018
24
Hepatoblastoma in a Child With Early-onset Cirrhosis. ( 29420370 )
2018
25
Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. ( 29922990 )
2018
26
MicroRNA-17, MicroRNA-19b, MicroRNA-146a, MicroRNA-302d Expressions in Hepatoblastoma and Clinical Importance. ( 29889802 )
2018
27
Right trisegmentectomy after portal vein embolization in a high-risk toddler with hepatoblastoma. ( 29600326 )
2018
28
X-Linked Severe Combined Immunodeficiency and Hepatoblastoma: A Case Report and Review of Literature. ( 29620683 )
2018
29
Hepatocyte-Derived Lipocalin 2 Is a Potential Serum Biomarker Reflecting Tumor Burden in Hepatoblastoma. ( 29920228 )
2018
30
Therapeutic experience with hepatoblastoma associated with trisomy 18. ( 29701292 )
2018
31
Addition of Vincristine and Irinotecan to Standard Therapy in a Patient With Refractory High-risk Hepatoblastoma Achieving Long-term Relapse-free Survival. ( 29668545 )
2018
32
Hepatoblastoma in patients with molecularly proven familial adenomatous polyposis: Clinical characteristics and rationale for surveillance screening. ( 29719120 )
2018
33
Pretransplant trends in I+-fetoprotein levels as a predictor of recurrence after living donor liver transplantation for unresectable hepatoblastoma: A single-institution experience. ( 29761829 )
2018
34
Ginsenoside Rg1 impairs homologous recombination repair by targeting CtBP-interacting protein and sensitizes hepatoblastoma cells to DNA damage. ( 29952772 )
2018
35
Eluding liver transplantation in POSTTEXT III and IV Hepatoblastoma. ( 29906299 )
2018
36
18F-FDG PET/CT for Molecular Imaging of Hepatoblastoma in Beckwith-Wiedemann Syndrome. ( 29485435 )
2018
37
MiR-492 regulates metastatic properties of hepatoblastoma via CD44. ( 29314711 )
2018
38
Cytomegalovirus infection in pediatric patients with hepatoblastoma after liver transplantation. ( 30051556 )
2018
39
Comparison between infantile hepatic hemangioendothelioma and hepatoblastoma in pediatric patients: clinical manifestations and contrast-enhanced computed tomography features. ( 30302991 )
2018
40
A Brief Report of Immunohistochemical Markers to Identify Aggressive Hepatoblastoma. ( 28187036 )
2018
41
Surgical Resection for Hepatoblastoma-Updated Survival Outcomes. ( 28963691 )
2018
42
Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis. ( 29138840 )
2018
43
New insights into diagnosis and therapeutic options for proliferative hepatoblastoma. ( 29152775 )
2018
44
Hepatoblastoma incidence in Taiwan: A population-based study. ( 29459224 )
2018
45
Kockdown of OIP5-AS1 expression inhibits proliferation, metastasis and EMT progress in hepatoblastoma cells through up-regulating miR-186a-5p and down-regulating ZEB1. ( 29475118 )
2018
46
Hepatoblastoma with pure fetal epithelial differentiation in a 10-year-old boy: A rare case report and review of the literature. ( 29480877 )
2018
47
Inhibition of cell migration by focal adhesion kinase: Time-dependent difference in integrin-induced signaling between endothelial and hepatoblastoma cells. ( 29484384 )
2018
48
Serum microRNA miR-206 is decreased in hyperthyroidism and mediates thyroid hormone regulation of lipid metabolism in HepG2 human hepatoblastoma cells. ( 29484422 )
2018
49
Overexpression of UHRF1 promotes silencing of tumor suppressor genes and predicts outcome in hepatoblastoma. ( 29507645 )
2018
50
Isoorientin triggers apoptosis of hepatoblastoma by inducing DNA double-strand breaks and suppressing homologous recombination repair. ( 29524880 )
2018

Variations for Hepatoblastoma

ClinVar genetic disease variations for Hepatoblastoma:

6 (show all 15)
# Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh37 Chromosome 5, 112175474: 112175474
2 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh38 Chromosome 5, 112839777: 112839777
3 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
4 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
5 CTNNB1 NM_001904.3(CTNNB1): c.121A> G (p.Thr41Ala) single nucleotide variant Conflicting interpretations of pathogenicity, other rs121913412 GRCh37 Chromosome 3, 41266124: 41266124
6 CTNNB1 NM_001904.3(CTNNB1): c.121A> G (p.Thr41Ala) single nucleotide variant Conflicting interpretations of pathogenicity, other rs121913412 GRCh38 Chromosome 3, 41224633: 41224633
7 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
8 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh38 Chromosome 3, 41224606: 41224606
9 CTNNB1 NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val) single nucleotide variant Conflicting interpretations of pathogenicity rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
10 CTNNB1 NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val) single nucleotide variant Conflicting interpretations of pathogenicity rs28931589 GRCh38 Chromosome 3, 41224613: 41224613
11 CTNNB1 NM_001904.3(CTNNB1): c.84_95delGTCTTACCTGGA (p.Gln28_Asp32delinsHis) deletion other GRCh38 Chromosome 3, 41224596: 41224607
12 MN1 NM_002430.2(MN1): c.927_929delGCA (p.Gln309del) deletion other rs747503495 GRCh38 Chromosome 22, 27799615: 27799617
13 MN1 NM_002430.2(MN1): c.927_929delGCA (p.Gln309del) deletion other rs747503495 GRCh37 Chromosome 22, 28195603: 28195605
14 ARID1A NM_006015.5(ARID1A): c.6259G> A (p.Gly2087Arg) single nucleotide variant other GRCh37 Chromosome 1, 27106648: 27106648
15 ARID1A NM_006015.5(ARID1A): c.6259G> A (p.Gly2087Arg) single nucleotide variant other GRCh38 Chromosome 1, 26780157: 26780157

Copy number variations for Hepatoblastoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48501 11 1 52900000 Methylation H19 Hepatoblastoma
2 48504 11 1 52900000 Methylation IGF2 Hepatoblastoma

Expression for Hepatoblastoma

Search GEO for disease gene expression data for Hepatoblastoma.

Pathways for Hepatoblastoma

Pathways related to Hepatoblastoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 APC CASP3 CTNNB1 HGF IGF2 TP53
2
Show member pathways
12.71 APC BIRC5 CASP3 CTNNB1 TP53
3
Show member pathways
12.55 APC CASP3 CTNNB1 HGF TP53
4
Show member pathways
12.4 ABCB1 APC CTNNB1 HGF IGF2 TP53
5 12.26 APC BIRC5 CTNNB1 TP53
6 12.22 APC BIRC5 CASP3 CTNNB1 HGF IGF2
7 11.95 AFP APC BIRC5 CTNNB1
8
Show member pathways
11.91 APC CTNNB1 GPC3 TP53
9 11.83 AFP APC HGF TP53
10 11.77 APC BIRC5 CASP3 CTNNB1 TP53
11 11.67 APC CTNNB1 IGF2 TP53
12 11.58 BIRC5 CASP3 TP53
13 11.4 APC CASP3 TP53
14 11.4 CASP3 CTNNB1 GPC3 HGF IGF2 TP53
15 11.36 BIRC5 CASP3 TP53
16 11.02 APC CTNNB1 HGF
17 10.63 ABCB1 TP53

GO Terms for Hepatoblastoma

Cellular components related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-catenin destruction complex GO:0030877 8.96 APC CTNNB1
2 Wnt signalosome GO:1990909 8.62 APC CTNNB1

Biological processes related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 BIRC5 CASP3 CTNNB1 HGF TP53
2 cytokine-mediated signaling pathway GO:0019221 9.73 BIRC5 CASP3 HGF TP53
3 negative regulation of transcription, DNA-templated GO:0045892 9.72 BIRC5 CDKN1C CTNNB1 PPARA TP53
4 negative regulation of inflammatory response GO:0050728 9.65 APOA1 HGF PPARA
5 cellular protein metabolic process GO:0044267 9.46 AFP APOA1 GPC3 IGF2
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 HGF IGF2 TP53
7 anterior/posterior axis specification GO:0009948 9.4 CTNNB1 GPC3
8 striated muscle cell differentiation GO:0051146 9.37 CASP3 IGF2
9 embryonic placenta morphogenesis GO:0060669 8.96 CDKN1C IGF2
10 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 8.8 APC CASP3 CDKN1C

Molecular functions related to Hepatoblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CASP3 CDKN1C

Sources for Hepatoblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....